Pharmacoeconomics

3.9(top 10%)

impact factor

3.4K(top 5%)

papers

106.5K(top 5%)

citations

124(top 5%)

h-index

4.1(top 10%)

impact factor

3.9K

all documents

112.3K

doc citations

205(top 5%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument	Pharmacoeconomics	1993	2,118
2	The Epidemiology of Obesity: A Big Picture	Pharmacoeconomics	2015	1,843
3	Conducting Discrete Choice Experiments to Inform Healthcare Decision Making	Pharmacoeconomics	2008	1,118
4	Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?	Pharmacoeconomics	2016	819
5	Determining Clinically Important Differences in Health Status Measures	Pharmacoeconomics	1999	767
6	The health economics of bladder cancer	Pharmacoeconomics	2003	725
7	An Introduction to Markov Modelling for Economic Evaluation	Pharmacoeconomics	1998	713
8	Multi-Attribute Health Status Classification Systems	Pharmacoeconomics	1995	702
9	Handling Uncertainty in Cost-Effectiveness Models	Pharmacoeconomics	2000	659
10	The NICE Cost-Effectiveness Threshold	Pharmacoeconomics	2008	643
11	A Comparative Review of Generic Quality-of-Life Instruments	Pharmacoeconomics	2000	627
12	The Burden of Schizophrenia on Caregivers	Pharmacoeconomics	2008	592
13	The Economic Costs of Type 2 Diabetes: A Global Systematic Review	Pharmacoeconomics	2015	588
14	Discrete Choice Experiments in Health Economics: A Review of the Literature	Pharmacoeconomics	2014	560
15	Epidemiology and burden of illness of rheumatoid arthritis	Pharmacoeconomics	2004	503
16	Multi-Attribute Preference Functions	Pharmacoeconomics	1995	457
17	Discrete Choice Experiments in Health Economics: Past, Present and Future	Pharmacoeconomics	2019	420
18	The Concept of Clinically Meaningful Difference in Health-Related Quality of Life Research	Pharmacoeconomics	2000	417
19	A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials	Pharmacoeconomics	2014	417
20	Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment	Pharmacoeconomics	2006	390
21	Neuropathic Pain	Pharmacoeconomics	2009	373
22	Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis	Pharmacoeconomics	2006	352
23	Cost-Effectiveness Analysis and the Consistency of Decision Making	Pharmacoeconomics	2001	341
24	The Health-Related Quality of Life and Economic Burden of Constipation	Pharmacoeconomics	2005	316
25	German Value Set for the EQ-5D-5L	Pharmacoeconomics	2018	316
26	Healthcare Resource and Lost Labour Costs of Migraine Headache in the US	Pharmacoeconomics	1992	308
27	The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	Pharmacoeconomics	2021	302
28	Use of Indirect and Mixed Treatment Comparisons for Technology Assessment	Pharmacoeconomics	2008	299
29	Cost-of-Illness Studies	Pharmacoeconomics	2011	291
30	A Practical Guide for Calculating Indirect Costs of Disease	Pharmacoeconomics	1996	290
31	Standardisation of Costs	Pharmacoeconomics	2002	290
32	Generic Health-Related Quality-of-Life Assessment in Children and Adolescents	Pharmacoeconomics	2006	284
33	Valuation of the Child Health Utility 9D Index	Pharmacoeconomics	2012	280
34	How to Calculate Indirect Costs in Economic Evaluations	Pharmacoeconomics	1998	276
35	A Review of Self-Report Instruments Measuring Health-Related Work Productivity	Pharmacoeconomics	2004	271
36	Cost-of-Illness Studies	Pharmacoeconomics	1992	264
37	Comparative Effectiveness Without Head-to-Head Trials	Pharmacoeconomics	2010	247
38	The Cost and Impact of Health Conditions on Presenteeism to Employers	Pharmacoeconomics	2009	245
39	Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs	Pharmacoeconomics	2007	241
40	A Review of Health-Related Workplace Productivity Loss Instruments	Pharmacoeconomics	2004	233
41	Health Utilities Using the EQ-5D in Studies of Cancer	Pharmacoeconomics	2007	232
42	Returns on Research and Development for 1990s New Drug Introductions	Pharmacoeconomics	2002	230
43	Medicaid Preferred Drug Lists: Cost Containment and Side Effects	Pharmacoeconomics	2006	229
44	Cost-of-Illness Studies	Pharmacoeconomics	2006	226
45	Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample	Pharmacoeconomics	1998	225
46	Costs of Irritable Bowel Syndrome in the UK and US	Pharmacoeconomics	2006	225
47	A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries	Pharmacoeconomics	2004	219
48	Using Value of Information Analysis to Prioritise Health Research	Pharmacoeconomics	2006	218
49	European Healthcare Policies for Controlling Drug Expenditure	Pharmacoeconomics	2003	217
50	Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries	Pharmacoeconomics	2018	215

Scientometrics

Overviews

Citing Bodies

Pharmacoeconomics

Top Articles